

Lymphatic Targeting Technology™ Solural Pharma ApS

- Many lipophilic drugs have difficult oral absorption due to low solubility and/or low permeability over the intestinal membrane. (BSC class II and IV drugs)
- Solural Pharma has developed a new formulation technology that utilizes the lymphatic absorption pathway for lipids. Lymphatic absorption from the upper GI tract by-passes CYP metabolism and P-gp efflux pumps in the GI membrane as well as first pass metabolism.
- Huge food-effect for lymphatic absorption has traditionally limited the usefulness of this path for drug absorption
- The Solural Pharma formulation system has the advantage of eliminating the severe food effect thus opening perspectives for using this absorption path for lipophilic drugs with difficult absorption characteristics
- Solural Pharma has filed a number of patent applications for new improved drug products based on this technology

Solural \ Pharr


The water insoluble, but fat soluble, drug substance is formulated in a solution (Self Emulsifying Drug Delivery System) consisting of :

- Triglyceride long chain fat
 - ✓ Secure the triggering of the lymphatic absorption system in the small intestine and dissolve the drug substance
- Glycerol monoester of long chain fatty acid
 - ✓ Supports the lymphatic triggering and being a fat soluble surfactant, it secures a homogenous formulation
- Biological acceptable water-soluble surfactant
 - ✓ Secure the formulation will mix with water to a homogenous micro-emulsion

The formulation is a liquid, and can conveniently be dosed as hard or soft gelatin capsules







SEDDS FORMULATION SPECIFIC COMPOSED TO TRIGGER OPTIMAL LYMPHATIC ABSORPTION



A Clinically Validated Technology

